Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders ... treatment of epidermal growth factor receptor driven ...

These changes, such as mutations in the epidermal growth factor receptor (EGFR), provide specific ... delivery method for ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of aurora kinase A, for breast cancer treatment. In this trial, alisertib ...

AstraZeneca, a global biopharmaceutical company is in collaboration with Revna Biosciences (www.RevnaBio.com), a precision medicine research and advanced diagnostics company to provide EGFR (Epidermal ...

Although many ecDNA-encoded oncogenes and their protein products, such as epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1), are validated drug targets for ...

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease ...

Dr. Chakraborty and his team report that mutations in the Epidermal Growth Factor Receptor (EGFR ... future patients may benefit from a routine blood test that would determine the level of ...